硅醚保护产物:甲氧基-M3
Erythromycin,6-O-methyl-2',4''-bis-O-(trimethylsilyl)-, 9-[O-(1-ethoxy-1-methylethyl)oxime];6-O-Methyl-2',4''-bis-O-(trimethylsilyl)-9-[O-(1-ethoxy-1-methylethyl)oxime];6-O-Methyl-2',4''-bis-O-(trimethylsilyl)erythromycin- 9-[O-(1-ethoxy-1-methylethyl)oxime];Intermediate of Clarithromycin;6-O-Methyl-2',4''-bis-O-(trimethylsilyl)-9-[O-(1-ethoxy-1-methylethyl)oxime]-Erythromycin;6-O-Methyl-2',4''-bis-O-(trimethylsilyl)erythromycin 9-[O-(1-ethoxy-1-methylethyl)oxime];9-[O-(1-ethoxy-1- methylethy) oxime;Erythromycin,6-O-methyl-2`,4``-bis-O-(trimethylsilyl),9-[O-(1-ethoxy-1-methylethyl) oxime;DS-1405;PUBCHEM_52915086;(3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-6-methyl-3-[(trimethylsilyl)oxy]oxan-2-yl]oxy}-10-{[(2-ethoxypropan-2-yl)oxy]imino}-14-ethyl-12,13-dihydroxy-7-methoxy-4-{[(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-[(trimethylsilyl)oxy]oxan-2-yl]oxy}-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecan-2-one;6-O-Methyl-2',4''-bis-O-(trimethylsilyl)erythromycin-9-[O-(1-ethoxy-1-methylethyl)oxime];AKOS015920282;IntermediateofClarithromycin;Erythromycin, 6-O-methyl-2',4''-bis-O-(trimethylsilyl)-, 9-[O-(1-ethoxy-1-methylethyl)oxime];Erythromycin,6-O-methyl-2',4''-bis-O-(trimethylsilyl)-,9-[o-(1-ethoxy-1-methylethyl)oxime];Erythromycin,6-O-methyl-2',4''-bis-O-(trimethylsilyl)-,9-[O-(1-ethoxy-1-methylethyl)oxime;119665-62-2;DTXSID70680611;(3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-6-methyl-3-trimethylsilyloxyoxan-2-yl]oxy-10-(2-ethoxypropan-2-yloxyimino)-14-ethyl-12,13-dihydroxy-7-methoxy-4-[(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-trimethylsilyloxyoxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one;Clarithromycin Impurity 39